Compare Stocks

→ Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$5.64 -0.7%	$5.87	$2.68 ▼ $8.22	$179.41M	3.96	311,904 shs	275,588 shs
ICOTF iCo Therapeutics	$0.38 -2.6%	$0.37	$0.80 ▼ $1.82	$3.42M	2.03	4,760 shs	15,000 shs
NVUS Novus Therapeutics	$2.80 +1.8%	$13.23	$4.50 ▼ $27.32	$4.02M	2.07	78,851 shs	142,914 shs
TRPX Therapix Biosciences	$0.10	$0.23	$0.25 ▼ $4.69	$351K	N/A	1.59 million shs	95,212 shs
XTLB XTL Biopharmaceuticals	$2.60 -1.5%	$3.99	$1.73 ▼ $6.69	$14.17M	1.19	12,888 shs	6,141 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	0.00%	-5.18%	+3.84%	+21.63%	+24.84%
ICOTF iCo Therapeutics	0.00%	+16.15%	+18.00%	-26.35%	-12.19%
NVUS Novus Therapeutics	0.00%	-2.48%	+19.57%	+70.81%	+42.49%
TRPX Therapix Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
XTLB XTL Biopharmaceuticals	0.00%	+1.15%	+4.35%	+225.28%	+112.90%

Next President (Not Trump. Not Biden.) (Ad)

Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.

Click here to see why it will be ______ _________.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	1.0936 of 5 stars	3.5	0.0	0.0	0.0	2.7	0.8	0.6
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.00	Buy	$21.75	285.64% Upside
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ICOTF, CAPR, NVUS, TRPX, and XTLB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/17/2024	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
5/14/2024	CAPR Capricor Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $25.00
5/14/2024	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
5/14/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
4/25/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00

(Data available from 6/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$25.18M	7.13	N/A	N/A	$0.73 per share	7.73
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	$13.13 per share	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	$0.41 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$22.29M	-$0.87	N/A	N/A	N/A	-89.72%	-231.68%	-50.83%	8/5/2024 (Estimated)
ICOTF iCo Therapeutics	-$1.11M	-$0.40	N/A	∞	N/A	N/A	N/A	-288.85%	N/A
NVUS Novus Therapeutics	-$16.01M	-$21.58	N/A	N/A	N/A	N/A	-133.49%	-30.52%	N/A
TRPX Therapix Biosciences	-$4.79M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	-$1.78M	N/A	0.00	∞	N/A	N/A	-73.05%	-68.83%	8/8/2024 (Estimated)

Latest ICOTF, CAPR, NVUS, TRPX, and XTLB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2024	Q1 2024	XTLB XTL Biopharmaceuticals	N/A	$0.10	+$0.10	$0.10	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A
TRPX Therapix Biosciences	N/A	N/A	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	1.57	1.57
ICOTF iCo Therapeutics	N/A	0.72	0.72
NVUS Novus Therapeutics	N/A	18.78	18.78
TRPX Therapix Biosciences	N/A	N/A	N/A
XTLB XTL Biopharmaceuticals	N/A	11.43	11.43

Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
ICOTF iCo Therapeutics	N/A
NVUS Novus Therapeutics	N/A
TRPX Therapix Biosciences	14.32%
XTLB XTL Biopharmaceuticals	4.40%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	12.00%
ICOTF iCo Therapeutics	N/A
NVUS Novus Therapeutics	2.20%
TRPX Therapix Biosciences	N/A
XTLB XTL Biopharmaceuticals	29.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	N/A	31.81 million	27.99 million	Optionable
ICOTF iCo Therapeutics	N/A	9.05 million	N/A	Not Optionable
NVUS Novus Therapeutics	7	1.44 million	N/A	Not Optionable
TRPX Therapix Biosciences	9	3.51 million	N/A	Not Optionable
XTLB XTL Biopharmaceuticals	N/A	5.45 million	3.87 million	Not Optionable

ICOTF, CAPR, NVUS, TRPX, and XTLB Headlines

Recent News About These Companies

April 26, 2024 | wsj.com

XTL Biopharmaceuticals Ltd. ADR

March 20, 2024 | msn.com

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03%

March 20, 2024 | msn.com

US Stocks Edge Lower Ahead Of Fed's Decision; General Mills Earnings Top Views

March 20, 2024 | markets.businessinsider.com

Dow Surges 350 Points; Fed Holds Rates Steady

March 20, 2024 | markets.businessinsider.com

Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher

March 20, 2024 | globenewswire.com

XTL To Aquire The Social Proxy

February 17, 2024 | investing.com

XTL Biopharmaceuticals Ltd ADR (XTLB)

February 11, 2024 | raps.org

Call for Proposals

October 23, 2023 | finance.yahoo.com

XTL Biopharmaceuticals Ltd (H2K2.MU)

October 23, 2023 | finanznachrichten.de

XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

October 21, 2023 | finanznachrichten.de

XTL Biopharmaceuticals Ltd.: XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

October 20, 2023 | finance.yahoo.com

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

October 20, 2023 | finance.yahoo.com

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

March 30, 2023 | aaii.com

Is X T L Biopharmaceuticals Ltd (ADR) (XTLB) Stock a Good Investment?

October 1, 2022 | seekingalpha.com

XTLB XTL Biopharmaceuticals Ltd.

August 8, 2022 | reuters.com

X T L Biopharmaceuticals Ltd

July 23, 2022 | seekingalpha.com

LIFE, TBLT and XTLB among pre market gainers

December 18, 2021 | ycharts.com

XTL Biopharmaceuticals Year to Date Total Returns (Daily)

December 18, 2021 | ycharts.com

XTL Biopharmaceuticals Dividend Per Share (TTM)

December 15, 2021 | uk.finance.yahoo.com

XTL Biopharmaceuticals Ltd. (XTLB)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks You Can Buy Before They Become Big
May 6, 2024 8:00 AM
View 3 Value Stocks You Can Buy Before They Become Big
3 Stocks Nancy Pelosi Has Been Buying
May 10, 2024 8:35 AM
View 3 Stocks Nancy Pelosi Has Been Buying
3 Affordable Stocks That Won’t Stay Down Much Longer
May 13, 2024 9:12 AM
View 3 Affordable Stocks That Won’t Stay Down Much Longer
3 Reasons Nvidia is on The Verge of a 4 Digit Stock Price
May 17, 2024 8:39 AM
View 3 Reasons Nvidia is on The Verge of a 4 Digit Stock Price
Canada Goose Flies Higher Driven By DTC Growth
May 20, 2024 6:25 AM
View Canada Goose Flies Higher Driven By DTC Growth

All Headlines

Company Descriptions

Capricor Therapeutics

NASDAQ:CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

iCo Therapeutics

OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Novus Therapeutics

NASDAQ:NVUS

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Therapix Biosciences

NASDAQ:TRPX

XTL Biopharmaceuticals

NASDAQ:XTLB

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial